Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. Bolous NS, Bhatt N, Bhakta N, et al. Gene therapy and hemophilia: where do we go from here? J Blood Med. 2022;13:559–80.
2. Shah J, Kim H, Sivamurthy K, et al. Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B. Curr Med Res Opin. 2022;39(2):227–37.
3. Thornburg CD. Etranacogene dezaparvovec for hemophilia B gene therapy. Ther Adv Rare Dis. 2021;2:1–14.
4. US Food & Drug Administration. FDA approves first gene therapy to treat adults with hemophilia B [media release]. 22 Nov 2022. https://www.fda.gov/.
5. European Medicines Agency. First gene therapy to treat haemophilia B [media release]. 16 Dec 2022. https://www.ema.europa.eu/en/news/first-gene-therapy-treat-haemophilia-b.
Cited by
40 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献